Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin versus placebo for intra-abdominal yeast infection in ICU patients
2018-000407-16Phase 3Active
- Sponsor
- CHU Amiens-Picardie
- Start
- Nov 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Intra-abdominal candidiasis (IAC) comparing Caspofungin arm with Placebo arm (2 arms). Primary endpoint: 28-day failure rate after the beginning of treatment. Started Nov 2018; status: active.
02
Drugs
caspofungin
03
Conditions
Intra-abdominal candidiasis (IAC)
Beyond the preview
Go deeper on 2018-000407-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000407-16.